XML 93 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions and Divestitures - 2016 Acquisitions (Details)
$ in Millions
12 Months Ended
Aug. 24, 2018
Dec. 20, 2017
product
Aug. 02, 2016
USD ($)
Mar. 01, 2016
USD ($)
Jan. 22, 2016
USD ($)
May 01, 2015
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Business Acquisition [Line Items]                  
Finite lived assets, useful life 20 years                
Research and development             $ 218.6 $ 167.7 $ 184.0
Benzaclin                  
Business Acquisition [Line Items]                  
Percentage of interest acquired     60.90%            
Purchase price paid     $ 62.0            
Benzaclin | Distribution and license agreements and supply agreements                  
Business Acquisition [Line Items]                  
Finite lived assets, useful life     9 years            
Tretinoin Products                  
Business Acquisition [Line Items]                  
Purchase price paid         $ 416.4        
Tretinoin Products | Developed product technology, formulations, and product rights                  
Business Acquisition [Line Items]                  
Finite lived assets, useful life         20 years        
Tretinoin Products | Non-compete agreements                  
Business Acquisition [Line Items]                  
Finite lived assets, useful life         5 years        
Development-Stage Rx Products                  
Business Acquisition [Line Items]                  
Research and development           $ 18.0      
Contingent consideration       $ 24.9          
Number of products sold | product   1              
Development-Stage Rx Products | Minimum                  
Business Acquisition [Line Items]                  
Royalty payment period       7 years          
Development-Stage Rx Products | Maximum                  
Business Acquisition [Line Items]                  
Royalty payment period       10 years